Erdosteine is a mucolytic agent used to treat respiratory tract infections. However, it is important to ensure that the drug is free of impurities that could affect its efficacy and safety. Erdosteine impurities can include related substances, degradation products, and residual solvents. These impurities may arise during manufacturing, storage, or handling of the drug. Therefore, it is essential to conduct thorough impurity profiling and control during the drug development process to ensure the quality, purity, and
